In the biotech sector,
Genmab A/S shows a mixed performance. It is generating interest with
strong quarterly results in 2025, an anticipated upward trend and buy ratings from H.C. Wainwright and Truist Securities. However, it experienced a drop in share prices possibly due to disappointing J&J cancer data and market volatility. Interestingly, Genmab's popularity among millennials is noted. The investment firm completed an
$8 billion acquisition of Merus, which led to a surge in stock prices though some analysts downgrade Merus's stock due to the deal.
William Blair remains bullish on Genmab despite short interest in the company's depositary receipt stock increasing. Projections indicate potential for rallies up to 33.8% to 39.97%, particularly following
FDA breakthrough approval for one of its products and proven robust demand for Darzalex. Meanwhile, attention shifts towards aspects such as dividend growth and the total return potential of the stock. Despite the oscillating view, most reports suggest a generally positive outlook for Genmab.
Genmab Stocks News Analytics from Sat, 08 Feb 2025 08:00:00 GMT to Sat, 01 Nov 2025 17:23:27 GMT -
Rating 5
- Innovation 3
- Information 7
- Rumor -1
